Hepatocellular carcinoma (HCC), a prevalent and often fatal liver cancer, presents significant treatment challenges, especially in its advanced stages. This article delves into the promising approach of combining immunotherapy, particularly immune checkpoint inhibitors, with radiation therapy, a cornerstone of HCC management. Our review synthesizes current preclinical and clinical research, highlighting the potential synergistic effects of this combinational treatment. Emerging evidence suggests that this synergy enhances tumor control and improves patient survival rates. The combination leverages the localized, tumor-targeting ability of radiation therapy and the systemic, immune-boosting effects of immunotherapy, potentially overcoming the limitations inherent in each treatment modality when used separately. This integrative approach is especially promising in addressing the complex tumor microenvironment of HCC. However, the treatment landscape is nuanced, with challenges such as patient-specific response variability and potential resistance to therapies. Future research directions should focus on refining these combination strategies, tailoring them to individual patient profiles, and understanding the underlying mechanisms that govern the interaction between immunotherapy and radiation therapy. Such advancements could significantly improve HCC management, setting new standards for patient care and treatment efficacy.
肝细胞癌（HCC）作为一种常见且高致死性的肝癌，尤其在晚期阶段面临显著的治疗挑战。本文深入探讨了将免疫疗法（特别是免疫检查点抑制剂）与作为HCC治疗基石的放射疗法相结合的潜力策略。本综述综合了当前临床前及临床研究，重点阐述了该联合治疗方案可能产生的协同效应。新近证据表明，这种协同作用可增强肿瘤控制并提高患者生存率。该联合疗法结合了放射治疗的局部靶向能力与免疫疗法的全身性免疫增强效应，有望克服两种疗法单独使用时固有的局限性。这种整合性策略在应对HCC复杂的肿瘤微环境方面尤其具有前景。然而，该治疗领域仍存在诸多复杂性，包括患者个体反应差异及潜在治疗耐药性等挑战。未来研究方向应聚焦于优化联合治疗策略、实现个体化精准治疗，并深入理解免疫疗法与放射治疗相互作用的潜在机制。这些进展有望显著改善HCC的治疗现状，为患者护理和疗效评估树立新标准。
Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma
肿瘤(癌症)患者之家